新型萊姆病疫苗在第三期臨床試驗中展現成效
New Lyme Disease Vaccine Shows Promise in Phase 3 Trial
2026年3月，醫療研究取得重大突破，輝瑞與Valneva宣布了其萊姆病疫苗候選者VLA15的第3期試驗結果。
A significant breakthrough in medical research occurred in March 2026, as Pfizer and Valneva announced the Phase 3 results for their Lyme disease vaccine candidate, VLA15.
萊姆病是北半球最常見的病媒傳染病，但目前尚無核准供人類使用的疫苗。
Lyme disease is the most common vector-borne illness in the Northern Hemisphere, yet there is currently no approved vaccine available for human use.
VALOR臨床試驗在北美與歐洲招募了近9500名參與者，以測試該疫苗的效力。
The VALOR clinical trial tested the vaccine's efficacy in nearly 9,500 participants across North America and Europe.
此疫苗的作用機制獨特：它能誘導產生抗體，在蜱蟲吸血時進入其體內，在細菌到達人類宿主前，先在中腸將其消滅。
The vaccine works through a unique mechanism: it induces antibodies that enter a tick while it feeds, neutralizing the bacteria inside the tick’s midgut before it can reach the human host.
自最初的疫苗在二十多年前停產以來，此候選疫苗代表了應對這一迫切健康需求的最有希望的努力，為高風險地區的戶外活動安全帶來了希望。
This candidate represents the most promising effort to address this urgent health need since the original vaccine was discontinued over two decades ago, offering hope for safer outdoor activities in high-risk regions.
